Related Experiment Video
Updated: Aug 5, 2025
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Current status and patent prospective of lipid nanoparticle for mRNA delivery
1Central International Intellectual Property (Baotou) Co., Ltd., Baotou, China.
Introduction:
Messenger RNA-lipid nanoparticle (mRNA-LNP) delivery is currently a research hotspot in pharmaceutics. LNP has emerged in pharmaceutical industry as popular and effective vehicle for mRNA delivery. It is therefore significant to understand current landscape and recent development of LNP for mRNA delivery.
Areas Covered:
This article provides patent landscape and recent development for mRNA-LNP delivery by US-granted patent analysis. The US-granted patents from January 2003 to December 2022 were retrieved and analyzed by using PatSnap.
Expert Opinion:
Globally, the present article was the first one which showed that mRNA-LNP delivery system demonstrated three therapeutic applications including vaccines, anticancer, and diseases associated with protein or enzyme deficiencies. ModernaTX is the most powerful company and leads almost all technologies in mRNA-LNP field. In addition, the technologies related to LNP for mRNA delivery are virtually controlled by top three assignees. mRNA-LNP delivery in therapy of diseases associated with enzyme deficiencies may be a future trend. The article provides recent advances in LNP for mRNA delivery.
